Canaph Therapeutics

Canaph Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation cytokine therapies for cancer and autoimmune diseases. The company utilizes its proprietary Syn-Kine platform to engineer cytokine fusion proteins with improved pharmacological properties, aiming to overcome the historical limitations of toxicity and short half-lives associated with native cytokines. Its lead programs focus on optimized versions of Interleukin-2 (IL-2) and Interleukin-12 (IL-12) designed to selectively activate immune cells within the tumor microenvironment. By leveraging deep expertise in protein engineering, Canaph seeks to provide safer and more effective immunotherapy options for patients with hard-to-treat malignancies.